KPV

KPV (α-MSH fragment) is a tripeptide. The HEIVE catalog describes it as: The anti-inflammatory tail of α-MSH without the pigmentation activity, studied mostly in colitis models. It is also known as α-MSH 11-13 and Lys-Pro-Val.

HEIVE groups KPV under inflammation, gut healing, tissue repair, immune balance and infection recovery. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for KPV under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for KPV lists: Very few reported. Mild GI upset orally. Longer-term concerns: Unknown beyond a few months of use. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

KPV has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for KPV: 200–500 mcg daily, oral or subcutaneous. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies KPV as mainly preclinical. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists oral or topical for KPV. A listed form is not evidence of an approved or effective treatment.

Preparation of KPV depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for KPV depends on the specific formulation (oral, injectable and topical in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for KPV: None described. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

KPV and LL-37 share the catalog categories immune balance, infection recovery and inflammation. KPV: The anti-inflammatory tail of α-MSH without the pigmentation activity, studied mostly in colitis models. LL-37: The body's own antimicrobial peptide, cut from cathelicidin. It kills pathogens outright and then tells the immune system what to do next. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View LL-37

The HEIVE editorial summary highlights: Antimicrobial activity against Candida turned up in work on inflammation. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.